Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: Results of the United Kingdom MRC AML-15 trial

Blood

Volumn 120, Issue 14, 2012, Pages 2826-2835

  Liu Yin, John A ^a   O'Brien, Michelle A ^a   Hills, Robert K ^b   Daly, Sarah B ^a   Wheatley, Keith ^c   Burnett, Alan K ^b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR; CYTARABINE; GEMTUZUMAB OZOGAMICIN; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PATIENT IDENTIFICATION; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84867297401     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-435669     Document Type: Article

References (47)

1. Swerdlow SH, Campo E, Harris NL, et al (eds). WHO Classification of Haematopoetic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. Blood. 1998;96(13):4075-4083.
3. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21) (q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17(12): 3767-3775.
4. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).Blood. 2002;100(13):4325-4336. (Pubitemid 35429670)
5. Byrd JC, Ruppert AS, Mrozek, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16) (p13q22) or t(16;16): results from CALGB 8461. J Clin Oncol. 2004;22(6):1087-1094. (Pubitemid 41095042)
6. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22(18):3741-3750. (Pubitemid 41102131)
7. Marcucci G, Mrozek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B Study. J Clin Oncol. 2005; 23(24):5705-5717.
8. Liu Yin JA, Grimwade D. Minimal residual disease evaluation in acute myeloid leukemia. Lancet. 2002;360:160-162. (Pubitemid 34786209)
9. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe against cancer program. Leukemia. 2003;17(12):2318-2357. (Pubitemid 38072573)
10. Schnittger S, Weisser M, Schoch C, Hiddemann W, Halerlach T, Kern W. New score predicting for prognosis in PML-RARA, AML1-ETO, or CBFBMYH11 acute myeloid leukemia based on quantification of fusion transcripts. Blood. 2003;102(8): 2746-2755. (Pubitemid 37248843)
11. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27(22):3650- 3658.
12. Tobal K, Frost L, Liu Yin JA. Quantification of DEK-CAN fusion transcript by real-time reverse transcription polymerase chain reaction in patients with t(6;9) acute myeloid leukemia. Haematologica. 2004;89(10):1267-1269. (Pubitemid 39390457)
13. Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real-time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 2002;16(10):2115-2121.
14. Grimwade D, Vyas P, Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol. 2010;22(6):656-663.
15. Brüggermann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107(3):1116-1123.
16. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship in other prognostic factors: a Children's Oncology Group Study. Blood. 2008; 111(12):5477-5485.
17. Müller MC, Cross NC, Erben P, et al. Harmonisation of molecular monitoring of CML therapy in Europe. Leukemia. 2009;23(11):1957-1963.
18. Corbacioglu A, Scholl C, Schlenk RF, et al. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol. 2010;28(23):3724-3729.
19. Krönke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol. 2011;29(19):2709-2716.
20. Tobal K, Liu Yin JA. Monitoring of minimal residual disease by quantitative reverse transcriptase polymerase chain reaction for AML-MTG8 transcripts in AML-M2 with t(8;21). Blood. 1996; 88(10):3704-3709. (Pubitemid 26383092)
21. Tobal K, Newton J, Macheta M, et al. Molecular quantification of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood. 2000;95(3):815-819. (Pubitemid 30062701)
22. Buonamici S, Ottaviani E, Testoni N, et al. Real-time quantification of minimal residual disease in inv(16) positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood. 2002;99(2):443-449.
23. Guerrasio A, Pilatrino C, De Micheli, et al. Assessment of minimal residual disease (MRD) in CBFB-MYH11 positive acute myeloid leukemia by quantitative RT-PCR amplification of fusion transcripts. Leukemia. 2002;16(6):1176-1181. (Pubitemid 34618856)
24. Krauter J, Gorlich K, Ottmann O, et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol. 2003;21(23):4413-4422. (Pubitemid 46621819)
25. Leroy H, de Botton S, Grardel-Duflos N, et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia. 2005; 19(3):367-372. (Pubitemid 40403312)
26. Stentoft J, Hokland P, Ostergaard M, Hasle H, Nyvold CG. Minimal residual core binding factor AML's by real time quantitative PCR: initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leuk Res. 2006;30(4):389-395. (Pubitemid 43254960)
27. Perea G, Lasa A, Aventin A, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favourable cytogenetics (t(8;21) and inv(16)). Leukemia. 2006; 20(1):87-94.
28. Weisser Haferlach C, Hiddeman W, Schnittger S. The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO positive AML and independent of pretreatment risk factors. Leukemia. 2007;21(16):1177-1182. (Pubitemid 46831805)
29. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukaemia who benefit from the addition of Gemtuzumab Ozogamicin: results of the MRC AML 15 Trial. J Clin Oncol. 2011;29(4):369-377.
30. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): a Europe Against Cancer Program. Leukemia. 2003;17(12):2474-2486. (Pubitemid 38072587)
31. Freeman SD, Jovanovic JV, Grimwade D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol. 2008;35(4):388-400.
32. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24): 4642-4649. (Pubitemid 46594039)
33. Mantel N, Byar DP. Evaluation of response-time data involving transient states: an illustration using heart-transplant data. J Am Stat Assoc. 1974; 69:81-86.
34. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long term remission. Blood. 1993;82(3):712-715. (Pubitemid 23221647)
35. Jurlander J, Caligiuri MA, Ruutu T, et al. Persistence of AML1-ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood. 1996;88(6):2183-2191. (Pubitemid 26307921)
36. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing non-leukemic stem cells in acute myelogenous leukaemia with 8;21 chromosome translocation. Proc Natl Acad Sci U S A. 2000; 97(13):7521-7526. (Pubitemid 30431496)
37. Tobal K, Johnson PRE, Saunders MJ, et al. Detection of CBF beta/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br J Haematol. 1995;91(1):104-108.
38. Elmaagacli AH, Beelen DW, Kroll M, et al. Detection of CBF beta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukaemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation. Bone Marrow Transplant. 1998;21:159-166. (Pubitemid 28044009)
39. Liu Yin JA. Minimal residual disease in acute myeloid leukaemia. Baillieres Best Pract Res Clin Haematol. 2002;15(1):119-135.
40. Borthakur G, Faderl S, Verstovsek S. Molecular response in core binding factor acute myelogenous leukaemia with fludarabine, cytarabine, G-CSF and gemtuzumab ozogamicin. Blood. 2008;112:676.
41. Breems DA, Van Putten WLT, Huijens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005; 23(9):1969-1978. (Pubitemid 46211376)
42. Marcucci G, Caligiuri MA, Dohner H, et al. Quantification of CBF beta/MYH11 fusion transcripts by real-time RT-PCR in patients with inv(16) acute myeloid leukaemia. Leukemia. 2001;15(7):1072-1080. (Pubitemid 32717277)
43. Martinelli G, Rondoni M, Buonamici S, et al. Molecular monitoring to identify a threshold of CBFbeta/ MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv 16 is likely. Haematologica. 2004;89(4):495-497. (Pubitemid 38798557)
44. Boeckx N, De Roover J, van der Velden, et al. Quantification of CBFB-MYH11 fusion gene levels in paired peripheral blood and bone marrow samples by real-time PCR. Leukemia. 2005; 19(11):1988-2022.
45. Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPMI mutation specific RQ-PCR provide important prognostic information in AML. Blood. 2009;14(11):2220-2231.
46. Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPMI c, PML-RARA, RUNXI-RUNXITI and CBFB-MYH11 acute myeloid leukemia. Blood. 2010;115(2):198-205.
47. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 24(24):3904-3911.